ArticleFrontiers in cardiovascular medicine2025
Case report and literature review of transthyretin amyloidosis with p.Ser43Asn mutation presenting in China.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hereditary transthyretin amyloid cardiomyopathy caused by the rare TTR p.Ser43Asn variant in an Asian family: a case report.Frontiers in cardiovascular medicine · 2026Article
- Case Report: Hereditary ATTR-CA presenting with recurrent severe abdominal cramps: a diagnostic challenge.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Familial transthyretin amyloidosis (ATTR) is a rare hereditary disorder marked by abnormal protein fibril deposits that impair multiple organ functions. Although over 130 mutations have been identified, the p.Ser43Asn variant, which has been associated with amyloidosis involving thyroxine-binding globulin (TBG), is scarcely reported in the literature, especially within the Chinese population. Case presentation: We report a case of a 50-year-old male presenting with recurrent episodes of amaurosis fugax. The patient had a family history of cardiac disease. Auxiliary examinations revealed myocardial hypertrophy, and the electrocardiogram indicated conduction delays and abnormal QRS complexes. Nuclear imaging suggested cardiac amyloidosis, and cardiac MRI indicated non-ischemic cardiomyopathy. Genetic testing identified a c.128G > A (p.Ser43Asn) mutation, and pathological examination confirmed ATTR amyloidosis. Both pathological findings and mass spectrometry analysis supported this diagnosis. Discussion: The p.Ser43Asn variant likely impacts TTR protein dimerization and stability, leading to protein misfolding and amyloid fibril deposition in tissues. Early diagnosis is crucial due to the significant heterogeneity of this condition. Our findings emphasize the importance of increased diagnostic awareness, multidisciplinary collaboration, and regional genetic screening. Comparisons with similar cases reported in the literature highlight the shared clinical presentations and diagnostic challenges. Conclusion: This case adds valuable insight into the clinical manifestations and diagnostic challenges of ATTR amyloidosis with the p.Ser43Asn mutation, particularly in the Chinese population. Future research should aim to develop effective treatment strategies and explore the genetic and environmental factors influencing the phenotypic variability of this rare disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.